Holen Sie sich die Stockscreener-App
2.80
1.75%
-0.05
Schlusskurs vom Vortag:
$2.85
Offen:
$2.88
24-Stunden-Volumen:
3.03M
Relative Volume:
1.05
Marktkapitalisierung:
$269.54M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-67.68M
KGV:
-1.6867
EPS:
-1.66
Netto-Cashflow:
$-54.24M
1W Leistung:
+11.55%
1M Leistung:
+30.23%
6M Leistung:
+63.74%
1J Leistung:
+3.70%
1-Tages-Spanne:
$2.745
$2.94
1-Wochen-Bereich:
$2.41
$2.94
52-Wochen-Spanne:
$0.9857
$3.67
Cabaletta Bio Inc Stock (CABA) Company Profile
Firmenname
Cabaletta Bio Inc
Sektor
Branche
Telefon
(267) 759-3100
Adresse
2929 ARCH STREET, PHILADELPHIA, PA
Compare CABA vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CABA
Cabaletta Bio Inc
|
2.80 | 274.36M | 0 | -67.68M | -54.24M | -1.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Cabaletta Bio Inc Stock (CABA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-10 | Fortgesetzt | Jefferies | Buy |
| 2024-12-20 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2024-12-19 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-10-10 | Eingeleitet | UBS | Buy |
| 2024-02-05 | Eingeleitet | Jefferies | Buy |
| 2023-11-29 | Eingeleitet | William Blair | Outperform |
| 2023-10-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-10-19 | Eingeleitet | Stifel | Buy |
| 2023-09-05 | Eingeleitet | Citigroup | Buy |
| 2023-07-18 | Eingeleitet | Guggenheim | Buy |
| 2023-01-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-08-30 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2021-10-19 | Fortgesetzt | Morgan Stanley | Overweight |
| 2021-06-30 | Eingeleitet | Mizuho | Buy |
| 2021-01-08 | Eingeleitet | Chardan Capital Markets | Buy |
| 2020-10-13 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-11-19 | Eingeleitet | Cowen | Outperform |
| 2019-11-19 | Eingeleitet | Evercore ISI | Outperform |
| 2019-11-19 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Cabaletta Bio Inc Aktie (CABA) Neueste Nachrichten
Pharma News: Why retail investors favor Cabaletta Bio Inc. stock2025 Historical Comparison & Fast Entry High Yield Tips - mfd.ru
Cabaletta Bio Kicks Off Pivotal Myositis Trial, Touts Automated CAR-T Manufacturing Path to 2027 BLA - Yahoo Finance
Is Anavex Life Sciences (AVXL) Stock Outpacing Its Medical Peers This Year? - Nasdaq
Aug Drivers: Is Cabaletta Bio Inc stock a smart retirement pickJuly 2025 Recap & Fast Moving Market Watchlists - baoquankhu1.vn
CABA News Today | Why did Cabaletta Bio stock go up today? - MarketBeat
Exit Recap: Is SpartanNash Company stock risky to hold nowJuly 2025 Review & Real-Time Volume Trigger Notifications - baoquankhu1.vn
Cabaletta Bio Takes Spotlight at Guggenheim Summit as Autoimmune Bet Advances - MyChesCo
Update Recap: Is Cabaletta Bio Inc stock overvalued or fairly priced2025 Macro Impact & AI Powered Market Entry Strategies - baoquankhu1.vn
Trend Review: Is Cabaletta Bio Inc stock overvalued or fairly pricedJuly 2025 Technicals & Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
Cabaletta Bio to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 - The Globe and Mail
Cabaletta Bio to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026 - Quiver Quantitative
Risk Off: What is Cabaletta Bio Incs P E ratio telling usJuly 2025 PostEarnings & Weekly High Return Stock Forecasts - baoquankhu1.vn
Swing Trade: Can Cabaletta Bio Inc deliver consistent dividendsQuarterly Earnings Summary & Free Real-Time Market Sentiment Alerts - baoquankhu1.vn
US Market Wrap: Can Cabaletta Bio Inc disrupt its industryJuly 2025 Outlook & Reliable Entry Point Alerts - baoquankhu1.vn
Highs Report: Will Tucows Inc outperform its industry peersMarket Activity Recap & Fast Moving Stock Trade Plans - baoquankhu1.vn
What makes Cabaletta Bio, Inc. (CABA) a strong momentum stock: Buy now? - MSN
What Makes Cabaletta Bio, Inc. (CABA) a Strong Momentum Stock: Buy Now? - Yahoo Finance
Cabaletta Bio, Inc. (NASDAQ:CABA) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Guggenheim reiterates Buy rating on Cabaletta Bio stock, citing commercial plan - Investing.com Nigeria
Cabaletta Bio: Do You Buy With The Insiders? (NASDAQ:CABA) - Seeking Alpha
Is Cabaletta Bio (CABA) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Largest borrow rate increases among liquid names - TipRanks
Assessing Cabaletta Bio (CABA) Valuation After Insider Buying And FDA Clearance For Automated CAR T Manufacturing - Yahoo Finance
Can Cabaletta Bio’s (CABA) Shift To Automated CAR T Manufacturing Redefine Its Scalability Edge? - simplywall.st
Stock Analysis: Does Cabaletta Bio Inc have pricing powerWeekly Trend Recap & Daily Growth Stock Investment Tips - baoquankhu1.vn
Strategic Partnerships Propel Cabaletta Bio Forward - StocksToTrade
Cabaletta Bio Unveils Strategic Plans Amid Price Target Revision - timothysykes.com
Cabaletta Bio Aims High with Strategic Initiatives for 2026 - StocksToTrade
Steven Nichtberger Bought 3.3% More Shares In Cabaletta Bio - Sahm
Returns Recap: Is Cabaletta Bio Inc stock trending bullishGap Down & Community Verified Trade Signals - baoquankhu1.vn
Cabaletta Bio Unveils Strategic Plans Amid Financial Forecast Changes - StocksToTrade
Cabaletta Bio Stock (CABA) Opinions on Insider Buying and Clinical Updates - Quiver Quantitative
Cabaletta targets 2027 FDA filing as autoimmune CAR-T push accelerates - MSN
Cabaletta Bio Advances Rese-cel Toward Pivotal Milestones, Expands Autoimmune Cell Therapy Pipeline - RTTNews
Why Cabaletta Bio (CABA) Is Up 41.3% After FDA Clears Automated CAR T Manufacturing Platforms - Yahoo Finance
Cabaletta Bio to Present Pioneering Clinical Data on Rese-cel at Major Scientific Conferences - MSN
Cabaletta Bio Sees Unusually Large Options Volume (NASDAQ:CABA) - MarketBeat
Cabaletta Bio (CABA) Shares Surge 11% After Insider Buying - GuruFocus
Cabaletta Bio stock jumps 11% premarket after insider buying cluster hits the tape - TechStock²
Cabaletta Bio, Inc. (NASDAQ:CABA) institutional owners may be pleased with recent gains after 9.7% loss over the past year - simplywall.st
Simon Mark, Cabaletta bio director, buys $25,261 in shares By Investing.com - Investing.com Nigeria
Cabaletta Bio (CABA) CEO Nichtberger buys $100,777 in shares By Investing.com - Investing.com UK
Biotech Stocks Surge After Hours: IO Biotech Jumps 19%, Cue Biopharma And Cabaletta Bio Follow - Nasdaq
Cabaletta Bio Insiders Go on a Buying Spree, Signaling Strong Confidence From the Top - TipRanks
Insider Buying: Michael Gerard Acquires Shares of Cabaletta Bio Inc (CABA) - GuruFocus
Insider Buying: Steve Gavel Acquires Shares of Cabaletta Bio Inc (CABA) - GuruFocus
Steven Nichtberger Acquires 45,000 Shares of Cabaletta Bio (NASDAQ:CABA) Stock - MarketBeat
Cabaletta Bio (NASDAQ:CABA) Director Mark Simon Acquires 11,061 Shares - MarketBeat
Cabaletta Bio (NASDAQ:CABA) Insider Gwendolyn Binder Buys 11,312 Shares - MarketBeat
Insider Buying: Cabaletta Bio (NASDAQ:CABA) Insider Acquires 8,800 Shares of Stock - MarketBeat
Michael Gerard Purchases 6,600 Shares of Cabaletta Bio (NASDAQ:CABA) Stock - MarketBeat
Finanzdaten der Cabaletta Bio Inc-Aktie (CABA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Cabaletta Bio Inc-Aktie (CABA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Binder Gwendolyn | President, Science & Tech. |
Jan 21 '26 |
Buy |
2.19 |
11,312 |
24,763 |
31,312 |
| Tomasello Shawn | Director |
Jan 21 '26 |
Buy |
2.21 |
22,725 |
50,322 |
22,725 |
| Gavel Steve | Chief Commercial Officer |
Jan 21 '26 |
Buy |
2.27 |
22,170 |
50,215 |
22,170 |
| Bollard Catherine | Director |
Jan 21 '26 |
Buy |
2.27 |
4,405 |
9,982 |
5,405 |
| Nichtberger Steven | President & CEO |
Jan 21 '26 |
Buy |
2.24 |
45,000 |
100,778 |
1,031,483 |
| Simon Mark | Director |
Jan 21 '26 |
Buy |
2.28 |
11,061 |
25,261 |
147,205 |
| Gerard Michael | General Counsel |
Jan 21 '26 |
Buy |
2.27 |
6,600 |
14,979 |
6,600 |
1.12%
0.87%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):